- Home
- HTT vs RLMD Comparison
HTT vs RLMD Comparison
Compare HTT & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HTT
High Templar Tech Limited American depositary shares each representing one Class A ordinary share
Current Price
Company Overview
Basic Information| Metric | HTT | RLMD |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 405.3M | 461.9M |
| IPO Year | 2017 | 2012 |
Fundamental Metrics
Financial Performance| Metric | HTT | RLMD |
|---|---|---|
| Price | $2.41 | $3.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.40 |
| AVG Volume (30 Days) | 73.7K | ★ 1.2M |
| Earning Date | 05-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,070.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.14 | ★ N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $1.88 | $1.80 |
| 52 Week High | $3.91 | $8.00 |
Technical Indicators
Market Signals| Indicator | HTT | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 38.77 | 31.32 |
| Support Level | $2.34 | $3.59 |
| Resistance Level | $2.69 | $4.51 |
| Average True Range (ATR) | 0.07 | 0.22 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 13.79 | 8.59 |
Price Performance
Historical ComparisonAbout HTT High Templar Tech Limited American depositary shares each representing one Class A ordinary share
High Templar Tech Ltd is an enabler of financial technology. High Templar is focusing on exploring business opportunities globally to satisfy clients' demand by leveraging its technology know-how and financial service capabilities. The company focus empowering financial institutions with its technological capabilities, helping them improve marketing and operational efficiency and efficiently connect their diverse financial products with online traffic.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.